JP2013510091A5 - - Google Patents

Download PDF

Info

Publication number
JP2013510091A5
JP2013510091A5 JP2012537218A JP2012537218A JP2013510091A5 JP 2013510091 A5 JP2013510091 A5 JP 2013510091A5 JP 2012537218 A JP2012537218 A JP 2012537218A JP 2012537218 A JP2012537218 A JP 2012537218A JP 2013510091 A5 JP2013510091 A5 JP 2013510091A5
Authority
JP
Japan
Prior art keywords
virus
cells
particle
polypeptide
respiratory syncytial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012537218A
Other languages
English (en)
Japanese (ja)
Other versions
JP5917402B2 (ja
JP2013510091A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/055334 external-priority patent/WO2011056899A2/en
Publication of JP2013510091A publication Critical patent/JP2013510091A/ja
Publication of JP2013510091A5 publication Critical patent/JP2013510091A5/ja
Application granted granted Critical
Publication of JP5917402B2 publication Critical patent/JP5917402B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012537218A 2009-11-03 2010-11-03 キメラＲＳＶ−Ｆポリペプチド、およびレンチウイルスＧａｇまたはアルファレトロウイルスＧａｇに基づくＶＬＰ Expired - Fee Related JP5917402B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25776609P 2009-11-03 2009-11-03
US61/257,766 2009-11-03
PCT/US2010/055334 WO2011056899A2 (en) 2009-11-03 2010-11-03 Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps

Publications (3)

Publication Number Publication Date
JP2013510091A JP2013510091A (ja) 2013-03-21
JP2013510091A5 true JP2013510091A5 (https=) 2013-12-19
JP5917402B2 JP5917402B2 (ja) 2016-05-11

Family

ID=43970730

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012537218A Expired - Fee Related JP5917402B2 (ja) 2009-11-03 2010-11-03 キメラＲＳＶ−Ｆポリペプチド、およびレンチウイルスＧａｇまたはアルファレトロウイルスＧａｇに基づくＶＬＰ

Country Status (5)

Country Link
US (1) US8920812B2 (https=)
EP (1) EP2496609A4 (https=)
JP (1) JP5917402B2 (https=)
CN (1) CN102753582A (https=)
WO (1) WO2011056899A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
EP2636413A1 (en) * 2012-03-09 2013-09-11 Ecole Normale Superieure De Lyon Chimeric virus-like particles (VLP) containing functional hMPV proteins
JP5805908B2 (ja) * 2012-03-22 2015-11-10 クルセル ホランド ベー ヴェー Ｒｓｖに対するワクチン
AU2013240248B2 (en) 2012-03-26 2018-12-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Delivery of packaged RNA to mammalian cells
CA2900110A1 (en) * 2013-02-01 2014-08-07 Medimmune, Llc Respiratory syncytial virus f protein epitopes
WO2015066715A1 (en) * 2013-11-04 2015-05-07 Viracell Advanced Products, Llc Virus-like particles and methods related thereto
CN106232807A (zh) 2013-12-16 2016-12-14 美利坚合众国, 由健康及人类服务部部长代表 通过使用vlp复制子投递ii类mhc抗原的癌症免疫疗法
CN104450631A (zh) * 2014-11-11 2015-03-25 中国人民解放军第四军医大学 肠道病毒ev71型vp1基因病毒样颗粒及其制备方法和应用
MX2019000725A (es) 2016-07-18 2019-07-04 Variation Biotechnologies Inc Composiciones de vacuna para tratamiento de virus zika.
HUE073526T2 (hu) 2017-04-04 2026-01-28 Univ Washington Önmagát összeállító fehérje nanostruktúrák, amelyek paramyxovírus és/vagy pneumovírus F fehérjéket jelenítenek meg és azok használata
DK3676285T3 (da) 2017-09-01 2026-01-19 Inprother Aps Vaccine til anvendelse i profylakse og/eller behandling af en sygdom
WO2019169120A1 (en) * 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
US12115219B2 (en) 2018-03-21 2024-10-15 The University Of North Carolina At Chapel Hill Compositions and methods for inhibiting pathogen infection
EP3873517A4 (en) 2018-10-29 2022-09-28 Emory University RSV VIRUS-LIKE PARTICLES AND METHODS OF PRODUCTION THEREOF
KR20230008707A (ko) 2020-03-30 2023-01-16 배리에이션 바이오테크놀로지스 아이엔씨. 코로나바이러스 치료용 백신 조성물
WO2022261149A2 (en) 2021-06-09 2022-12-15 Scribe Therapeutics Inc. Particle delivery systems
WO2024254544A2 (en) * 2023-06-07 2024-12-12 Nvelop Therapeutics, Inc. Compositions and methods for promoting payload delivery in cells
CN117777314B (zh) * 2024-02-26 2024-05-14 赛德特生物制药有限公司 慢病毒载体及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4484969B2 (ja) 1996-11-26 2010-06-16 ヌベンタ バイオファーマスティカル コーポレイション ストレスタンパク質を含む組成物を使用する免疫応答
US6099847A (en) 1997-05-15 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric Gag pseudovirions
WO2002000693A2 (en) 2000-06-23 2002-01-03 The Government Of The United States Of America Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
MXPA02012254A (es) 2000-06-23 2003-04-25 American Cyanamid Co Montaje de particulas quimericas semejantes al virus de influenza y del tipo silvestre.
EP1201750A1 (en) 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
AU2002309100A1 (en) 2001-03-12 2002-11-18 Proteologics, Ltd. Compositions and methods for the modulation of viral maturation
EP2280074A3 (en) 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
UA82998C2 (ru) 2002-05-16 2008-06-10 Бавариан Нордик А/С Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті
WO2004042001A2 (en) 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
BR0311995A (pt) 2002-06-20 2005-04-05 Cytos Biotechnology Ag Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
GB0226722D0 (en) 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8574590B2 (en) 2003-07-30 2013-11-05 Integral Molecular, Inc. Lipoparticles comprising proteins, methods of making, and using the same
US8437251B2 (en) 2005-12-22 2013-05-07 Qualcomm Incorporated Methods and apparatus for communicating transmission backlog information
EP2044198A4 (en) 2006-07-27 2010-09-08 Ligocyte Pharmaceuticals Inc CHIMERIC INFLUENZA VIRUS TYPE PARTICLES
CA2657955A1 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
WO2008061243A2 (en) 2006-11-16 2008-05-22 Novavax, Inc. Respiratory syncytial virus-virus like particle (vlps)
DE102006060799A1 (de) * 2006-12-21 2008-06-26 RUHR-UNIVERSITäT BOCHUM RSV F-Protein und seine Verwendung
CA2678966A1 (en) 2007-02-21 2008-08-28 Novavax, Inc. Chimeric newcastle disease virus vlps

Similar Documents

Publication Publication Date Title
JP2013510091A5 (https=)
Zhang et al. A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques
Tornesello et al. Virus-like particles as preventive and therapeutic cancer vaccines
US20230023093A1 (en) Dna antibody constructs and method of using same
US20220112273A1 (en) DNA Antibody Constructs And Method Of Using Same
US10087240B2 (en) DNA antibody constructs and method of using same
JP2009544318A5 (https=)
US20250011401A1 (en) Optimized nucleic acid antibody constructs
KR102604877B1 (ko) 감염성 질환의 예방 및/또는 치료와 종양학적 질환의 치료를 위한 약독화된 인플루엔자 벡터
JP2010528601A5 (https=)
JP2012526839A5 (https=)
Ross et al. Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference
Pandey et al. Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses
CA3085627C (en) Ebola virus and marburg virus glycoprotein mucin-like domain replacement expression system used as new vaccine approaches
WO2022192594A2 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
Wang et al. Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines
Schell et al. Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody
Di Vincenzo Determinants of the Antibody Response against HIV Env induced by Nanoparticle Vaccination and Intrastructural Help
WO2019035972A1 (en) SEQUENTIAL IMMUNIZATIONS WITH HIV-1 ENV VIRUS TYPE PARTICLES
CN117043182A (zh) 经修饰的抗病毒结合剂
TW202246317A (zh) 針對呼吸道融合病毒及其他副黏液病毒的抗體以及使用其之方法
Peng A novel vaccine strategy: Replication-defective pseudotyped SIVs expressing IFN-γ